Cargando…
Complementing the Cancer-Immunity Cycle
Reactivation of cytotoxic CD8(+) T-cell responses has set a new direction for cancer immunotherapy. Neutralizing antibodies targeting immune checkpoint programmed cell death protein 1 (PD-1) or its ligand (PD-L1) have been particularly successful for tumor types with limited therapeutic options such...
Autores principales: | Pio, Ruben, Ajona, Daniel, Ortiz-Espinosa, Sergio, Mantovani, Alberto, Lambris, John D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473060/ https://www.ncbi.nlm.nih.gov/pubmed/31031765 http://dx.doi.org/10.3389/fimmu.2019.00774 |
Ejemplares similares
-
Complement in Metastasis: A Comp in the Camp
por: Ajona, Daniel, et al.
Publicado: (2019) -
The Complement System in Ovarian Cancer: An Underexplored Old Path
por: Senent, Yaiza, et al.
Publicado: (2021) -
The Challenges and Promise of Complement Therapeutics for Ocular Diseases
por: Park, Dong Ho, et al.
Publicado: (2019) -
Editorial: Therapeutic Modulation of the Complement System: Clinical Indications and Emerging Drug Leads
por: Mastellos, Dimitrios C., et al.
Publicado: (2020) -
Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge
por: Senent, Yaiza, et al.
Publicado: (2021)